Dr. Reddy’s Laboratories has delayed the supply of its semaglutide products after identifying a quality issue with the active pharmaceutical ingredient (API), pushing back planned shipments and triggering a decline in the company’s share price.
The Hyderabad-based drugmaker said the issue relates to a specific batch of the API used to manufacture semaglutide, a widely prescribed medicine for type 2 diabetes and weight management. The company stressed that the problem was detected during its quality checks and that patient safety remains its top priority.
As a precaution, Dr. Reddy’s has decided to postpone supplies until the issue is fully resolved and fresh batches meet all quality standards. The company did not disclose how long the delay would last but said it is working closely with suppliers and regulators to address the problem at the earliest.
The announcement comes at a time when demand for semaglutide-based medicines is rising rapidly across global markets. Pharmaceutical companies have been expanding production capacity to meet growing demand for diabetes and obesity treatments, making any disruption in supply closely watched by investors and healthcare providers.
Following the announcement, shares of Dr. Reddy’s came under pressure as investors assessed the potential impact on near-term sales and product launches. Analysts, however, noted that the delay appears to be linked to quality control rather than regulatory action, highlighting the company’s decision to prioritise compliance and product safety.
Dr. Reddy’s has not indicated any impact on its broader product portfolio and reiterated its commitment to delivering high-quality medicines. The company said it will resume supplies once the affected API issue is resolved and manufacturing meets the required quality benchmarks.
Also Read: Rupee gains 15 paise despite RBI’s dollar challenge
